Tangen Biosciences receives a Notice of Intent to fund the SBIR/NIH phase I grant application for Rapid Detection of Multiple Sepsis Pathogens.
Tangen Biosciences holds Pre-Submission meeting with FDA to discuss parameters for the clinical testing of the TangenDx direct-from-blood Fungal Panel in support of a planned 510(k) submission.
Tangen Biosciences has commenced the process of securing FDA clearance for its novel molecular diagnostic platform by submitting a Pre-Submission Package to the Center for Devices and Radiological Health of the Food and Drug Administration.
Tangen successfully demonstrates the TangenDx Fungal Sepsis Panel at three clinical microbiology labs in the northeast region.
Tangen Biosciences, Inc., has been awarded a Phase I SBIR grant from the National Institutes of Health to develop a rapid molecular assay for the detection of Multiple Drug Resistant Mycobacteria Tuberculosis (MDR-TB) in sputum. The grant will fund the development of specific primers to identify 15 different SNPs in the TB genome that confer resistance to front line TB antibiotics. The drug sensitivity test will be added into the existing Tangen TB assay to create a panel that will include accurate diagnosis of TB along with comprehensive drug sensitivity information. The MDR-TB assay panel will run on a single disposable disk in the TangenDx Instrument, a battery powered, portable, low cost, highly sensitive and simple to use molecular diagnostic platform.
Tangen completes $2MM Seed Round equity financing http://www.hartfordbusiness.com/article/20151229/NEWS01/151229911/tangen-biosciences-raises-2m-in-equity-funding